ABSTRACT
Background and aim: Roux-en-Y gastric bypass (RYGB) is an effective treatment for weight loss in patients with morbid obesity. However, few studies have assessed its long-term efficacy in super-obese patients. The study objective was to analyse the long-term effectiveness of RYGB and its effect on improvement of comorbidities after 10 years of follow-up, and to compare the results depending on baseline BMI (<50kg/m2 vs ≥50kg/m2). Patients and methods: A retrospective study was conducted in 63 patients referred for RYGB with a 10-year or longer follow-up period. Mean BMI before surgery was 55kg/m2. Results: Mean BMI decreased to 38.1kg/m2 at 10 years of follow-up. The success rates according to Reinhold criteria modified by Christou and to Biron's criteria were 30.2% and 54% respectively. The corresponding rates in super-obese patients were 21.4% and 57.1%. Significant, stable improvement was seen in diabetes, dyslipidemia, hypertension, and sleep apnea. Conclusions: Sustained weight loss was achieved after gastric bypass, with a mean excess weight loss of 50.6% after 10 years despite the high prevalence of super-obesity. Comorbidity improvement was maintained (AU)
Antecedentes y objetivos: El baipás gástrico en Y de Roux (RYGB) es un tratamiento efectivo para la pérdida de peso en pacientes con obesidad mórbida. Sin embargo, en pocos estudios se ha evaluado su eficacia a largo plazo en pacientes con superobesidad (IMC ≥ 50kg/m2). El objetivo es analizar la efectividad del RYGB, su efecto sobre la mejoría de las comorbilidades tras 10 años de seguimiento y comparar los resultados en función del IMC inicial (<50kg/m2 vs ≥ 50kg/m2). Pacientes y métodos: Se realizó un estudio retrospectivo sobre 63 pacientes remitidos a RYGB con periodo de seguimiento igual o superior a 10 años. El IMC medio precirugía fue 55kg/m2. Resultados: El IMC medio descendió a 38,1kg/m2 a los 10 años de seguimiento. Las tasas de éxito según los criterios de Reinhold modificados por Christou y según los criterios de Biron fueron 30,2 y 54%. En pacientes con superobesidad estas tasas fueron 21,4 y 57,1%. Se observó remisión estable y significativa de la diabetes, hipertensión y apnea del sueño. Conclusiones:Tras la cirugía bariátrica se consiguió pérdida de peso sostenida, con un porcentaje de exceso de peso perdido de 50,6% a los 10 años a pesar de la alta prevalencia de superobesidad. La mejoría de las comorbilidades permaneció estable (AU)
Subject(s)
Humans , Obesity/diagnosis , Obesity/epidemiology , Anthropometry/methods , Gastric Bypass/methods , Anastomosis, Roux-en-Y/methods , Bariatric Surgery/methods , Comorbidity , Cohort Studies , Retrospective Studies , Sleep Apnea Syndromes/complications , Hypertension/complications , Diabetes Mellitus/diagnosis , Weight Loss , 28599ABSTRACT
BACKGROUND AND AIM: Roux-en-Y gastric bypass (RYGB) is an effective treatment for weight loss in patients with morbid obesity. However, few studies have assessed its long-term efficacy in super-obese patients. The study objective was to analyse the long-term effectiveness of RYGB and its effect on improvement of comorbidities after 10 years of follow-up, and to compare the results depending on baseline BMI (<50kg/m2 vs ≥50kg/m2). PATIENTS AND METHODS: A retrospective study was conducted in 63 patients referred for RYGB with a 10-year or longer follow-up period. Mean BMI before surgery was 55kg/m2. RESULTS: Mean BMI decreased to 38.1kg/m2 at 10 years of follow-up. The success rates according to Reinhold criteria modified by Christou and to Biron's criteria were 30.2% and 54% respectively. The corresponding rates in super-obese patients were 21.4% and 57.1%. Significant, stable improvement was seen in diabetes, dyslipidemia, hypertension, and sleep apnea. CONCLUSIONS: Sustained weight loss was achieved after gastric bypass, with a mean excess weight loss of 50.6% after 10 years despite the high prevalence of super-obesity. Comorbidity improvement was maintained.
Subject(s)
Body Mass Index , Diabetes Mellitus, Type 2/epidemiology , Dyslipidemias/epidemiology , Gastric Bypass , Hypertension/epidemiology , Obesity, Morbid/surgery , Postoperative Complications/epidemiology , Sleep Apnea, Obstructive/epidemiology , Comorbidity , Follow-Up Studies , Obesity, Morbid/epidemiology , Postoperative Period , Prevalence , Remission Induction , Spain/epidemiology , Treatment Outcome , Weight LossABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Rett Syndrome/etiology , Cystectomy , Urinary Diversion , Nutrition Therapy , Epilepsy/diagnosis , Brain Diseases/diet therapySubject(s)
Acidosis/etiology , Brain Diseases, Metabolic/etiology , Hyperammonemia/etiology , Urinary Diversion/adverse effects , Acidosis/physiopathology , Aged , Ammonia/pharmacokinetics , Brain Diseases, Metabolic/physiopathology , Carcinoma, Transitional Cell/surgery , Dietary Proteins/administration & dosage , Dietary Proteins/pharmacokinetics , Epilepsy, Complex Partial/etiology , Female , Humans , Hydrogen-Ion Concentration , Hyperammonemia/diet therapy , Hyperammonemia/physiopathology , Intestinal Absorption , Plant Proteins, Dietary/administration & dosage , Urinary Bladder Neoplasms/surgerySubject(s)
Gastric Bypass/adverse effects , Hypoglycemia/etiology , Postgastrectomy Syndromes/etiology , Adult , Blood Glucose/analysis , Fasting/blood , Female , Glucagon-Like Peptide 1/metabolism , Humans , Hypoglycemia/blood , Hypoglycemia/physiopathology , Ileum/metabolism , Insulin/metabolism , Insulin Secretion , Obesity, Morbid/metabolism , Obesity, Morbid/surgery , Postgastrectomy Syndromes/blood , Postgastrectomy Syndromes/physiopathology , Postprandial Period , Recurrence , Reoperation , Secretory RateABSTRACT
No disponible
